Literature DB >> 26616058

Targeting HIF-1α is a prerequisite for cell sensitivity to dichloroacetate (DCA) and metformin.

Sung-Eun Hong1, Hyeon-Ok Jin2, Hyun-Ah Kim3, Min-Ki Seong3, Eun-Kyu Kim4, Sang-Kyu Ye5, Tae-Boo Choe6, Jin Kyung Lee2, Jong-Il Kim7, In-Chul Park8, Woo Chul Noh9.   

Abstract

Recently, targeting deregulated energy metabolism is an emerging strategy for cancer therapy. In the present study, combination of DCA and metformin markedly induced cell death, compared with each drug alone. Furthermore, the expression levels of glycolytic enzymes including HK2, LDHA and ENO1 were downregulated by two drugs. Interestingly, HIF-1α activation markedly suppressed DCA/metformin-induced cell death and recovered the expressions of glycolytic enzymes that were decreased by two drugs. Based on these findings, we propose that targeting HIF-1α is necessary for cancer metabolism targeted therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer metabolism; Dichloroacetate; Glycolytic enzymes; HIF-1α; Metformin

Mesh:

Substances:

Year:  2015        PMID: 26616058     DOI: 10.1016/j.bbrc.2015.11.088

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors:  Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

2.  Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.

Authors:  Vanitha N Sivalingam; Ayşe Latif; Sarah Kitson; Rhona McVey; Katherine G Finegan; Kay Marshall; Michael P Lisanti; Federica Sotgia; Ian J Stratford; Emma J Crosbie
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

3.  Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells.

Authors:  Rosalba Florio; Laura De Lellis; Serena Veschi; Fabio Verginelli; Viviana di Giacomo; Marialucia Gallorini; Silvia Perconti; Mario Sanna; Renato Mariani-Costantini; Angelica Natale; Arduino Arduini; Rosa Amoroso; Amelia Cataldi; Alessandro Cama
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

Review 4.  Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.

Authors:  Samson Mathews Samuel; Elizabeth Varghese; Peter Kubatka; Chris R Triggle; Dietrich Büsselberg
Journal:  Biomolecules       Date:  2019-12-09

Review 5.  Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas.

Authors:  Kristina M Cook; Han Shen; Kelly J McKelvey; Harriet E Gee; Eric Hau
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

6.  CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.

Authors:  Tongyuan Deng; Peng Shen; Aimin Li; Ziyan Zhang; Huiling Yang; Xiaojie Deng; Xuemei Peng; Zhe Hu; Zibo Tang; Jiahao Liu; Rentao Hou; Zhen Liu; Weiyi Fang
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.